A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF GSK573719/GW642444 AND GSK573719 IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD):